GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Equity-to-Asset
中文

Morphic Holding (Morphic Holding) Equity-to-Asset

: 0.97 (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Morphic Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $697.02 Mil. Morphic Holding's Total Assets for the quarter that ended in Dec. 2023 was $722.51 Mil.

The historical rank and industry rank for Morphic Holding's Equity-to-Asset or its related term are showing as below:

MORF' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.28   Med: 0.6   Max: 0.97
Current: 0.97

During the past 7 years, the highest Equity to Asset Ratio of Morphic Holding was 0.97. The lowest was -1.28. And the median was 0.60.

MORF's Equity-to-Asset is ranked better than
97.95% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs MORF: 0.97

Morphic Holding Equity-to-Asset Historical Data

The historical data trend for Morphic Holding's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.57 0.60 0.79 0.95 0.97

Morphic Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.97 0.97 0.97 0.97

Competitive Comparison

For the Biotechnology subindustry, Morphic Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Morphic Holding's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Equity-to-Asset falls into.



Morphic Holding Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Morphic Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=697.022/722.514
=0.96

Morphic Holding's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=697.022/722.514
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (NAS:MORF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Morphic Holding Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (Morphic Holding) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Executives
William Devaul officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin officer: CFO and COO ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni director, officer: President and CEO C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr officer: VP Finance and Ops, Secretary CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery director C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer director, 10 percent owner 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde officer: Chief Medical Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda director 281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal director C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Morphic Holding (Morphic Holding) Headlines

From GuruFocus